![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
ACH-2684 Demonstrates Potent Viral Suppression in Genotype 1 Hepatitis C Patients With and Without Cirrhosis: Safety, Pharmacokinetic, and Viral Kinetic Analysis
|
|
|
Reported by Jules Levin
EASL 2013 April 24-28 Amsterdam
Eric Lawitz1, John Hill2, Bradley Vince3, Abel Murillo4, Daniel Gruener5,Thomas Marbury6, Michael DeMicco7, Bao Zhang8,Atul Agarwal8, Heather Robison8, Mingjun Huang8, Lisa Robarge8,
James Hui8, Elizabeth Olek8 , Milind Deshpande8, Hetal S. Kocinsky8
1Alamo Medical Research, San Antonio, TX, 2Avail Clinical Research, DeLand; 3Vince and Associates Clinical Research, Overland Park, KS; 4AMPM Research Clinic, Miami, FL; 5CRI Worldwide, LLC,
Philadelphia, PA; 6Orlando Clinical Research Center, Orlando, FL; 7Anaheim Clinical Trials, Anaheim, CA; 8Achillion Pharmaceuticals, Inc., New Haven, CT
![EASL1.gif](../images/050913/050913-5/EASL1.gif)
![EASL2.gif](../images/050913/050913-5/EASL2.gif)
![EASL3.gif](../images/050913/050913-5/EASL3.gif)
![EASL4.gif](../images/050913/050913-5/EASL4.gif)
![EASL5.gif](../images/050913/050913-5/EASL5.gif)
![EASL6.gif](../images/050913/050913-5/EASL6.gif)
![EASL7.gif](../images/050913/050913-5/EASL7.gif)
![EASL8.gif](../images/050913/050913-5/EASL8.gif)
![EASL9.gif](../images/050913/050913-5/EASL9.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|